| 19.32 -0.77 (-3.83%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 38.21 | 1-year : | 52.09 |
| Resists | First : | 32.71 | Second : | 44.59 |
| Pivot price | 19  |
|||
| Supports | First : | 13.5 | Second : | 11.23 |
| MAs | MA(5) : | 20.05 |
MA(20) : | 23.7 |
| MA(100) : | 28.19  |
MA(250) : | 17.61 |
|
| MACD | MACD : | -3.9 |
Signal : | -4.1 |
| %K %D | K(14,3) : | 40.7 |
D(3) : | 31.2 |
| RSI | RSI(14): 36.8 |
|||
| 52-week | High : | 44.59 | Low : | 5.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ZBIO ] has closed below upper band by 46.4%. Bollinger Bands are 29.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.86 - 19.99 | 19.99 - 20.08 |
| Low: | 18.75 - 18.9 | 18.9 - 19.01 |
| Close: | 19.12 - 19.34 | 19.34 - 19.5 |
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
Fri, 23 Jan 2026
Zenas BioPharma (ZBIO) Stock Analysis: Promising 99.75% Upside Potential For Investors - directorstalkinterviews.com
Wed, 21 Jan 2026
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPhar - The National Law Review
Tue, 13 Jan 2026
Assessing Zenas BioPharma (ZBIO) Valuation After Phase 3 INDIGO Success And CEO Share Purchase - simplywall.st
Tue, 13 Jan 2026
Assessing Zenas BioPharma (ZBIO) Valuation After Positive INDIGO Phase 3 Trial News - Yahoo Finance
Sat, 10 Jan 2026
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 3.17e+007 (%) |
| Held by Institutions | 26.5 (%) |
| Shares Short | 4,860 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9562e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 304.6 % |
| Return on Equity (ttm) | -33.8 % |
| Qtrly Rev. Growth | 1.5e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 13.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -158 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 4.78e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|